Merck receives marketing authorization for NOBILIS
17 September 2014 | News | By BioSpectrum Bureau
Merck receives marketing authorization for NOBILIS
NOBILIS IB Primo QX will be the first vaccine developed using SPHEREON technology in the EU, which freeze-dries live vaccines to small, highly soluble particles (spheres) that allow for packaging in light-weight aluminum cups in convenient dose sizes, claims Merck in a media statement.
This vaccine is given to chickens from one day of age or older by spraying onto the chickens or by applying by eye-drop, and provides protection for eight weeks.
